肝细胞癌相关信号通路及靶向药物的研究进展  

Research progress of hepatocellular carcinoma associated signaling pathways and target agents

作　　者：刘晶晶[1,2,3,4] 牟艳玲[2,3,4] 

机构地区：[1]济南大学山东省医学科学院医学与生命科学学院,济南250200 [2]山东省医学科学院药物研究所,济南250062 [3]国家卫生部生物技术药物重点实验室,济南250062 [4]山东省罕少见病重点实验室,济南250062

出　　处：《生命科学》2017年第4期341-348,共8页Chinese Bulletin of Life Sciences

基　　金：山东省自主创新及成果转化专项(2014ZZCX 02105)

摘　　要：肝细胞癌是一种多阶段病变的消化系统恶性肿瘤,也是全球癌症发病率和死亡率的重要因素。尽管局部疗法,包括手术切除、肝移植、肝动脉栓塞术有了改善,但对于大多数患者而言,预后仍然很差。随着分子生物学的发展,分子疗法,诸如索拉菲尼、激酶抑制剂都对晚期肝癌患者的生存期有了改善。识别这些异常激活的信号通路,对理解导致肝癌发生的细胞过程和分子机制有很大帮助。现综述了参与肝细胞癌肿瘤形成、增殖和生存的多种信号通路及相关靶向药物,为肝细胞癌的治疗提供理论依据。Hepatoeellular carcinoma is a digestive system malignancy with multiple stages. It is a significant cause of cancer-related morbidity and mortality worldwide. Despite improvements in local therapies including surgical resection, liver transplantation, and transarterial embolization, the prognosis remains poor for the majority of patients. With the development of molecular biology, molecular therapies such as sorafenib, tyrosine kinase inhibitor, have been shown to improve survival in patients with advanced HCC. Research aimed at identifying aberrant activation of signaling pathways has led to significant progress in our understanding of cellular processes and molecular mechanisms that occur during multistage events that lead to hepatocarcinogenesis. This paper reviews the multiple pathways involved in HCC oncogenesis, proliferation and survival and relevant targeted agents, to provide theoretical basis for the treatment of hepatocellular carcinoma.

关 键 词：肝细胞癌 信号通路 靶向治疗 

分 类 号：R735.7[医药卫生—肿瘤] R979.1[医药卫生—临床医学]